LYEL
Lyell Immunopharma
获取预测
在您的设备上获取AI股票预测
关于该公司
Lyell Immunopharma specializes in cell therapy, focusing on the reprogramming of T-lymphocytes for the treatment of solid tumors. The company’s technologies are applicable regardless of biological targets and their associated pathways, and are utilized in chimeric antigen receptor (CAR) T-cell therapy, tumor-infiltrating lymphocyte (TIL) therapy, and T-cell receptor (TCR) therapy. Lyell Immunopharma is currently developing a pipeline of products designed to deliver comprehensive therapeutic effects across various forms of solid tumors that are difficult to treat.
立即获取AI股票预测
下载我们的AI股票预测实时应用
